ROIV ROIVANT SCIENCES LTD revenue, earnings and financials

For the quarter ended June 30, 2026, ROIVANT SCIENCES LTD reported revenue of $1.44M (down 33.5% from a year earlier), net income of −$190M and diluted EPS of −$0.26; over the last four quarters revenue was $7.53M and net income −$266M; for the fiscal year ended March 2026 revenue was $8.26M, down 71.6% on the year before.

ROIV annual revenue and earnings

• Fiscal year ended Mar 2026: revenue $8.26M, gross profit n/a, operating income −$515M, net income −$300M (margin -3629.2%), EPS −$0.54
• Fiscal year ended Mar 2025: revenue $29.1M, gross profit n/a, operating income −$1.00B, net income −$172M (margin -592.0%), EPS −$0.24
• Fiscal year ended Mar 2024: revenue $32.7M, gross profit n/a, operating income $4.50B, net income $4.35B (margin 13294.2%), EPS $5.23
• Fiscal year ended Mar 2023: revenue $31.5M, gross profit n/a, operating income −$907M, net income −$1.01B (margin -3200.2%), EPS −$1.42
• Fiscal year ended Mar 2022: revenue $55.3M, gross profit n/a, operating income −$1.35B, net income −$845M (margin -1528.9%), EPS −$1.26

ROIV quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $1.44M (down 33.5% year over year), net income −$190M, EPS −$0.26
• Quarter ended Mar 31, 2026 (from the annual report): revenue $2.52M (down 66.7% year over year), net income $303M, EPS $0.34
• Quarter ended Dec 31, 2025: revenue $2.00M (down 77.8% year over year), net income −$266M, EPS −$0.38
• Quarter ended Sep 30, 2025: revenue $1.57M (down 64.9% year over year), net income −$114M, EPS −$0.17
• Quarter ended Jun 30, 2025: revenue $2.17M (down 72.8% year over year), net income −$223M, EPS −$0.33
• Quarter ended Mar 31, 2025 (from the annual report): revenue $7.57M (up 193.2% year over year), net income −$206M, EPS −$0.28
• Quarter ended Dec 31, 2024: revenue $9.02M (down 42.1% year over year), net income $169M, EPS $0.23
• Quarter ended Sep 30, 2024: revenue $4.48M (up 22.7% year over year), net income −$230M, EPS −$0.31
• Quarter ended Jun 30, 2024: revenue $7.99M (down 63.1% year over year), net income $95.3M, EPS $0.12
• Quarter ended Mar 31, 2024 (from the annual report): revenue −$8.12M (down 242.1% year over year), net income −$151M, EPS −$0.02
• Quarter ended Dec 31, 2023: revenue $15.6M (down 8.7% year over year), net income $5.10B, EPS $6.03
• Quarter ended Sep 30, 2023: revenue $3.65M (down 70.9% year over year), net income −$304M, EPS −$0.40
• Quarter ended Jun 30, 2023: revenue $21.6M (up 400.7% year over year), net income −$292M, EPS −$0.38
• Quarter ended Mar 31, 2023 (from the annual report): revenue −$2.37M (down 125.7% year over year), net income −$33.6M, EPS −$0.03
• Quarter ended Dec 31, 2022: revenue $17.1M (down 29.9% year over year), net income −$352M, EPS −$0.49
• Quarter ended Sep 30, 2022: revenue $12.5M (down 10.4% year over year), net income −$292M, EPS −$0.42
• Quarter ended Jun 30, 2022: revenue $4.32M (down 44.2% year over year), net income −$332M, EPS −$0.48
• Quarter ended Mar 31, 2022 (from the annual report): revenue $9.22M, net income −$270M, EPS −$0.40
• Quarter ended Dec 31, 2021: revenue $24.3M, net income −$285M, EPS −$0.41
• Quarter ended Sep 30, 2021: revenue $14.0M, net income −$208M, EPS −$0.32

ROIV cash flow, buybacks and dividends

• Fiscal year ended Mar 2026: operating cash flow −$750M, share buybacks n/a
• Fiscal year ended Mar 2025: operating cash flow −$839M, share buybacks $1.29B
• Fiscal year ended Mar 2024: operating cash flow −$765M, share buybacks $0
• Fiscal year ended Mar 2023: operating cash flow −$843M, share buybacks $0
• Fiscal year ended Mar 2022: operating cash flow −$678M, share buybacks n/a

ROIV balance sheet

• Jun 30, 2026: cash $1.25B, total assets $5.31B, total liabilities $385M, shareholders' equity $4.23B
• Mar 31, 2026: cash $1.42B, total assets $5.71B, total liabilities $416M, shareholders' equity $4.53B
• Dec 31, 2025: cash $1.48B, total assets $5.23B, total liabilities $251M, shareholders' equity $4.27B
• Sep 30, 2025: cash $1.24B, total assets $5.06B, total liabilities $257M, shareholders' equity $4.36B
• Jun 30, 2025: cash $1.24B, total assets $5.03B, total liabilities $217M, shareholders' equity $4.35B
• Mar 31, 2025: cash $2.72B, total assets $5.44B, total liabilities $250M, shareholders' equity $4.69B
• Dec 31, 2024: cash $1.99B, total assets $5.79B, total liabilities $256M, shareholders' equity $5.19B
• Sep 30, 2024: cash $1.96B, total assets $6.21B, total liabilities $626M, shareholders' equity $5.15B

What is ROIV's revenue?

ROIVANT SCIENCES LTD reported $7.53M of revenue over its last four quarters, through June 30, 2026.

Is ROIV profitable?

No. ROIVANT SCIENCES LTD lost $266M over the last four quarters.

What is ROIV's EPS?

Diluted earnings per share over the last four quarters were −$0.47; −$0.26 in the latest quarter.

ROIV ownership and insider trades · All stocks